Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | SGK1 | O00141 | 11/20 | 0.34 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.34 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | CCR4 | P51679 | 1/20 | 0.34 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.33 |
| ▸ | TDO2 | P48775 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21545889 | 0.89 | TDO2 (0.39) | MEN1KMT2ASGK1SLC6A4NR3C1 | |
| SCHEMBL30286554 | 0.89 | TDO2 (0.39) | MEN1KMT2ASGK1SLC6A4NR3C1 | |
| SCHEMBL20354887 | 0.88 | MEN1 (0.45) | MEN1KMT2ASGK1SLC6A4POLB | |
| SCHEMBL30286594 | 0.86 | KMT2A (0.40) | MEN1KMT2ASGK1POLBMAPT | |
| SCHEMBL21545853 | 0.86 | KMT2A (0.40) | MEN1KMT2ASGK1POLBMAPT | |
| SCHEMBL21545876 | 0.85 | SGK1 (0.41) | MEN1KMT2ASGK1SLC6A4NR4A2 | |
| SCHEMBL30286626 | 0.85 | SGK1 (0.41) | MEN1KMT2ASGK1SLC6A4NR4A2 | |
| SCHEMBL28961597 | 0.84 | GPR17 (0.38) | SGK1SLC6A4NR3C1LMNANR4A2 | |
| SCHEMBL30614459 | 0.82 | TLR4 (0.38) | MEN1KMT2ASGK1POLB | |
| SCHEMBL20355181 | 0.81 | CCR2 (0.39) | SGK1POLBCCR4NR4A2TDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12071404-B2 | Aza (indole)-, benzothiophene-, and benzofuran-3-sulfonamides | UCB PHARMA GMBH (DE) | 2024-08-27 | — | — | US | claimed |
| CN-110121499-B | (aza) indole-, benzothiophene-and benzofuran-3-sulfonamides | 优时比制药有限公司 | 2022-12-20 | — | — | CN | claimed |
| US-11345662-B2 | Aza (indole)-, benzothiophene-, and benzofuran-3-sulfonamides | UCB PHARMA GMBH (DE) | 2022-05-31 | — | — | US | claimed |
| US-20220048858-A1 | Aza (Indole)-, Benzothiophene-, And Benzofuran-3-Sulfonamides | UCB PHARMA GMBH (DE) | 2022-02-17 | — | — | US | claimed |
| US-20190345104-A1 | Aza (Indole)-, Benzothiophene-, And Benzofuran-3-Sulfonamides | UCB PHARMA GMBH (DE) | 2019-11-14 | — | — | US | claimed |
| EP-3562820-A1 | (AZA)INDOLE-, BENZOTHIOPHENE-, AND BENZOFURAN-3-SULFONAMIDES | UCB Pharma GmbH (DE) | 2019-11-06 | — | — | EP | claimed |
| WO-2018122232-A1 | (AZA)INDOLE-, BENZOTHIOPHENE-, AND BENZOFURAN-3-SULFONAMIDES | UCB PHARMA GMBH (DE) | 2018-07-05 | — | — | WO | claimed |
| US-12071404-B2 | Aza (indole)-, benzothiophene-, and benzofuran-3-sulfonamides | UCB PHARMA GMBH (DE) | 2024-08-27 | — | — | US | disclosed |
| US-11820746-B2 | Aza (indole)-, benzothiophene-, and benzofuran-3-sulfonamides | UCB PHARMA GMBH (DE) | 2023-11-21 | — | — | US | disclosed |
| US-11820746-B2 | Aza (indole)-, benzothiophene-, and benzofuran-3-sulfonamides | UCB PHARMA GMBH (DE) | 2023-11-21 | — | — | US | disclosed |
| US-20230348384-A1 | Aza (Indole)-, Benzothiophene-, And Benzofuran-3-Sulfonamides | UCB PHARMA GMBH (DE) | 2023-11-02 | — | — | US | disclosed |
| US-20230348384-A1 | Aza (Indole)-, Benzothiophene-, And Benzofuran-3-Sulfonamides | UCB PHARMA GMBH (DE) | 2023-11-02 | — | — | US | disclosed |
| CN-116283712-A | (aza) indole-, benzothiophene-and benzofuran-3-sulfonamides | 优时比制药有限公司 | 2023-06-23 | — | — | CN | disclosed |
| US-20220127227-A1 | Aza (Indole)-, Benzothiophene-, And Benzofuran-3-Sulfonamides | UCB PHARMA GMBH (DE) | 2022-04-28 | — | — | US | disclosed |
| US-20220127227-A1 | Aza (Indole)-, Benzothiophene-, And Benzofuran-3-Sulfonamides | UCB PHARMA GMBH (DE) | 2022-04-28 | — | — | US | disclosed |
| US-20190345104-A1 | Aza (Indole)-, Benzothiophene-, And Benzofuran-3-Sulfonamides | UCB PHARMA GMBH (DE) | 2019-11-14 | — | — | US | disclosed |
| US-20190345104-A1 | Aza (Indole)-, Benzothiophene-, And Benzofuran-3-Sulfonamides | UCB PHARMA GMBH (DE) | 2019-11-14 | — | — | US | disclosed |
| EP-3562820-A1 | (AZA)INDOLE-, BENZOTHIOPHENE-, AND BENZOFURAN-3-SULFONAMIDES | UCB Pharma GmbH (DE) | 2019-11-06 | — | — | EP | disclosed |
| WO-2018122232-A1 | (AZA)INDOLE-, BENZOTHIOPHENE-, AND BENZOFURAN-3-SULFONAMIDES | UCB PHARMA GMBH (DE) | 2018-07-05 | — | — | WO | disclosed |
| WO-2018122232-A1 | (AZA)INDOLE-, BENZOTHIOPHENE-, AND BENZOFURAN-3-SULFONAMIDES | UCB PHARMA GMBH (DE) | 2018-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220127227-A1 | Aza (Indole)-, Benzothiophene-, And Benzofuran-3-Sulfonamides | GPR17, GPR18, GPR27 | MEN1 2601/4885KMT2A 1689/4885SGK1 3774/4885 |
| US-11345662-B2 | Aza (indole)-, benzothiophene-, and benzofuran-3-sulfonamides | GPR17, GPR18, GPR27 | MEN1 2601/4885KMT2A 1689/4885SGK1 3774/4885 |
| US-11820746-B2 | Aza (indole)-, benzothiophene-, and benzofuran-3-sulfonamides | GPR17, GPR18, GPR27 | MEN1 2601/4885KMT2A 1689/4885SGK1 3774/4885 |
| US-20220048858-A1 | Aza (Indole)-, Benzothiophene-, And Benzofuran-3-Sulfonamides | GPR17, GPR18, GPR27 | MEN1 2601/4885KMT2A 1689/4885SGK1 3774/4885 |
| US-20230348384-A1 | Aza (Indole)-, Benzothiophene-, And Benzofuran-3-Sulfonamides | GPR17, GPR18, GPR27 | MEN1 2601/4885KMT2A 1689/4885SGK1 3774/4885 |
| US-12071404-B2 | Aza (indole)-, benzothiophene-, and benzofuran-3-sulfonamides | GPR17, GPR18, GPR27 | MEN1 2601/4885KMT2A 1689/4885SGK1 3774/4885 |
| US-20190345104-A1 | Aza (Indole)-, Benzothiophene-, And Benzofuran-3-Sulfonamides | GPR17, GPR18, GPR27 | MEN1 2601/4885KMT2A 1689/4885SGK1 3774/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.